Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal


Suchbegriffe: TRASTUZUMAB - THERAPEUTIC USE, . Treffer: 4


Grillo, F; Fassan, M; Sarocchi, F; Fiocca, R; Mastracci, L HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice.
World J Gastroenterol. 2016; 22(26):5879-5887 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Ignatiadis, M; Rack, B; Rothé, F; Riethdorf, S; Decraene, C; Bonnefoi, H; Dittrich, C; Messina, C; Beauvois, M; Trapp, E; Goulioti, T; Tryfonidis, K; Pantel, K; Repollet, M; Janni, W; Piccart, M; Sotiriou, C; Litiere, S; Pierga, JY Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial.
Eur J Cancer. 2016; 63(10):97-104
Web of Science PubMed FullText FullText_MUG


Schramm, A; Friedl, TW; Schochter, F; Scholz, C; de Gregorio, N; Huober, J; Rack, B; Trapp, E; Alunni-Fabbroni, M; Müller, V; Schneeweiss, A; Pantel, K; Meier-Stiegen, F; Hartkopf, A; Taran, FA; Wallwiener, D; Janni, W; Fehm, T Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program.
Arch Gynecol Obstet. 2016; 293(2):271-281
Web of Science PubMed FullText FullText_MUG



Eisner, F; Pichler, M; Goletz, S; Stoeger, H; Samonigg, H A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options.
J Clin Pathol. 2015; 68(12):1044-1046 (- Case Report) [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


© Med Uni Graz Impressum